Published on September 5, 2013 at 11:00 AM
ThromboGenics has entered into a collaboration and license agreement with Bicycle Therapeutics to develop and commercialize drugs inhibiting a specific target for the treatment of ophthalmic diseases such as diabetic macular edema (DME). DME is a leading cause of adult vision loss, with a significant proportion of patients failing to respond adequately to existing therapies.
For many years, the standard of care has been to treat DME with laser photocoagulation to the macula. More recently, it has been shown that injectable intravitreal drugs that inhibit vascular endothelial growth factor (VEGF) are effective.
Bicycle's bicyclic peptides inhibit a target involved in vascular permeability, and selective inhibition of this target offers the potential to improve the treatment of DME. Bicyclic peptides have the affinity and specificity associated with antibodies, but they are much smaller and can be chemically synthesized. They have been shown to address targets not easily tractable with small molecules.
ThromboGenics has gained an exclusive license from Bicycle to undertake clinical development and commercialization of identified drug candidates. In addition, the companies will collaborate on the preclinical development of Bicycle's bicyclic peptide inhibitors.
ThromboGenics will pay Bicycle an undisclosed up-front fee. Bicycle is also eligible for development and regulatory milestone payments and royalties on sales of products resulting from the collaboration.
This article was reprinted from Genetic Engineering & Biotechnology News (GEN) with permission from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology News (GEN) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.